WebMay 8, 2024 · The high genomic instability of non-small cell lung cancer tumors leads to the rapid development of resistance against promising EGFR tyrosine kinase inhibitors (TKIs). A recently detected triple mutation compromises the activity of the gold standard third-generation EGFR inhibitors. We have prepared a set of trisubstituted imidazoles with a … WebApr 9, 2024 · Florian Wittlinger & Stefan A. Laufer. Pages: 1091-1103. Published online: 20 Jun 2024. Abstract for The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancer Full Text References …
Tahereh DAMGHANI PostDoc Position University at
WebJul 16, 2024 · Florian Wittlinger, Stefan A. Laufer. The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancer. Expert Opinion on Drug Discovery 2024 , 16 (10) , 1091-1103. WebFeb 11, 2024 · Florian Wittlinger Michael J Eck Acquired drug resistance in epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer is a persistent challenge in cancer therapy. cheap rainbow sandals online
Design of a “Two-in-One” Mutant-Selective Epidermal Growth …
WebOct 20, 2024 · Inhibitors targeting the epidermal growth factor receptor (EGFR) are an effective therapy for patients with non-small cell lung cancer harboring drug-sensitive activating mutations in the EGFR kinase domain. Drug resistance due to treatment-acquired mutations has motivated the development of successive generations of inhibitors that … WebJun 20, 2024 · Tuebingen Center for Academic Drug Discovery & Development, Institute of Pharmaceutical Sciences, Eberhard Karls Universität Tübingen, Tübingen, Germany. Expert Opinion on Drug Discovery , 20 Jun 2024, 16 (10): 1091-1103. DOI: 10.1080/17460441.2024.1936496 PMID: 34053372. WebFlorian WITTLING of Ruhr-Universität Bochum, Bochum (RUB) Contact Florian WITTLING cyberpunk red heavy melee weapon